Related references
Note: Only part of the references are listed.The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers
Y. Shida et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus
Herbert Struemper et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Wendy W. Cai et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Susan Manzi et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Nathanael L. Dirks et al.
CLINICAL PHARMACOKINETICS (2010)
Clinical Ramifications of the MHC Family Fc Receptor FcRn
Derry C. Roopenian et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans
Brian J. Anderson et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Michael P. Cancro et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects
Wendy G. Halpern et al.
TOXICOLOGICAL SCIENCES (2006)
Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus
J Zhang et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
